A Study to Evaluate the Efficacy and Safety of CP-101,606 in Subjects With an Acute Stroke

Pfizer

Status and phase: Terminated; Phase 2

Conditions: Stroke

Treatments: Drug: traxiprodil (CP-101,606)

Study type: Interventional

Funder types: Industry

Identifiers

NCT00073476

A1611005

Details and patient eligibility

About

The purpose of this study is to determine whether a new research medication is effective and safe for the treatment of acute stroke when given within 6 hours of the onset of stroke.

Sex: All

Ages: 40 to 90 years old

Volunteers: No Healthy Volunteers

Inclusion criteria

Males & females age 40-90 years

Enrolled in study within 6 hours of onset of stroke symptoms

Willing to sign informed consent form

No significant disabilities prior to stroke

Exclusion criteria

Treatment with t-PA (tissue plasminogen activator)

Premorbid modified rankin scale score of 2 or more

Trial design

Primary purpose: Treatment

Allocation: Randomized

Interventional model: Parallel Assignment

Masking: Double Blind